Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2009 Apr 15;2009(2):CD007060.
doi: 10.1002/14651858.CD007060.pub2.

Liver resection versus other treatments for neuroendocrine tumours in patients with resectable liver metastases

Kurinchi Selvan Gurusamy  1 , Rajarajan Ramamoorthy, Dinesh Sharma, Brian R Davidson
Affiliations

Liver resection versus other treatments for neuroendocrine tumours in patients with resectable liver metastases

Kurinchi Selvan Gurusamy et al. Cochrane Database Syst Rev. .

Abstract

Background: Neuroendocrine tumours are tumours of cells, which possess secretory granules and originate from the neuroectoderm. While liver resection is generally advocated in patients with resectable liver metastases, recent studies have shown good survival in patients with disseminated neuroendocrine tumours who underwent thermal ablation using radiofrequency.

Objectives: To determine the benefits and harms of liver resection versus other treatments in patients with resectable liver metastases from gastro-entero-pancreatic neuroendocrine tumours.

Search strategy: We searched The Cochrane Hepato-Biliary Group Controlled Trials Register, the Cochrane Central Register of Controlled Trials (CENTRAL) in The Cochrane Library, MEDLINE, EMBASE, Science Citation Index Expanded and LILACS until July 2008 for identifying the randomised trials.

Selection criteria: We considered only randomised clinical trials (irrespective of language, blinding, or publication status) comparing liver resection (alone or in combination with radiofrequency ablation or cryoablation) versus other interventions (chemotherapy, hormonotherapy, or immunotherapy) and those comparing liver resection and thermal ablation (radiofrequency ablation or cryoablation) in patients with resectable liver metastases from neuroendocrine tumours for the review.

Data collection and analysis: Two authors independently identified trials for inclusion.

Main results: We were unable to identify any randomised clinical trial suitable for inclusion in this review. We were also unable to identify any quasi-randomised studies, cohort studies, or case-control studies that could inform meaningfully.

Authors' conclusions: There is no evidence from randomised clinical trials comparing liver resection versus other treatments in patients with resectable liver metastases from gastro-entero-pancreatic neuroendocrine tumours. Liver resection appears to be the main stay curative treatment for neuroendocrine liver metastases based on non-randomised studies. Further randomised clinical trials comparing liver resection alone or in combination with chemoembolisation or radionuclide therapy are needed. Further randomised clinical trials comparing surgical resection and radiofrequency ablation in selected patients may also be appropriate.

PubMed Disclaimer

Conflict of interest statement

See sponsors of the review.

Update of

References

Additional references

Anthony 2002
    1. Anthony LB, Woltering EA, Espenan GD, Cronin MD, Maloney TJ, McCarthy KE. Indium‐111‐pentetreotide prolongs survival in gastroenteropancreatic malignancies. Seminars in Nuclear Medicine 2002;32(2):123‐32. - PubMed
Chung 2001
    1. Chung MH, Pisegna J, Spirt M, Giuliano AE, Ye W, Ramming KP, et al. Hepatic cytoreduction followed by a novel long‐acting somatostatin analog: a paradigm for intractable neuroendocrine tumors metastatic to the liver. Surgery 2001;130(6):954‐62. - PubMed
Clark 2002
    1. Clark OA, Castro AA. Searching the Literatura Latino Americana e do Caribe em Ciencias da Saude (LILACS) database improves systematic reviews. International Journal of Epidemiology 2002;31(1):112‐4. - PubMed
Coppa 2001
    1. Coppa J, Pulvirenti A, Schiavo M, Romito R, Collini P, Bartolomeo M, et al. Resection versus transplantation for liver metastases from neuroendocrine tumors. Transplantation Proceedings 2001;33(1‐2):1537‐9. - PubMed
Curley 2008
    1. Curley SA. Radiofrequency ablation versus resection for resectable colorectal liver metastases: time for a randomized trial?. Annals of Surgical Oncology 2008;15(1):11‐3. - PMC - PubMed
DeMets 1987
    1. DeMets DL. Methods for combining randomized clinical trials: strengths and limitations. Statistics in Medicine 1987;6(3):341‐50. - PubMed
DerSimonian 1986
    1. DerSimonian R, Laird N. Meta‐analysis in clinical trials. Controlled Clinical Trials 1986;7(3):177‐88. - PubMed
Egger 1997
    1. Egger M, Davey SG, Schneider M, Minder C. Bias in meta‐analysis detected by a simple, graphical test. BMJ (Clinical Research Ed.) 1997;315(7109):629‐34. - PMC - PubMed
Faiss 2003
    1. Faiss S, Pape UF, Bohmig M, Dorffel Y, Mansmann U, Golder W, et al. Prospective, randomized, multicenter trial on the antiproliferative effect of lanreotide, interferon alfa, and their combination for therapy of metastatic neuroendocrine gastroenteropancreatic tumors ‐ the International Lanreotide and Interferon Alfa Study Group. Journal of Clinical Oncology 2003;21(14):2689‐96. - PubMed
Falconi 1999
    1. Falconi M, Bassi C, Bonora A, Sartori N, Procacci C, Talamini G, et al. Role of chemoembolization in synchronous liver metastases from pancreatic endocrine tumours. Digestive Surgery 1999;16(1):32‐8. - PubMed
Fjallskog 2001
    1. Fjallskog ML, Granberg DP, Welin SL, Eriksson C, Oberg KE, Janson ET, et al. Treatment with cisplatin and etoposide in patients with neuroendocrine tumors. Cancer 2001;92(5):1101‐7. - PubMed
Florman 2004
    1. Florman S, Toure B, Kim L, Gondolesi G, Roayaie S, Krieger N, et al. Liver transplantation for neuroendocrine tumors. Journal of Gastrointestinal Surgery 2004;8(2):208‐12. - PubMed
Garrean 2007
    1. Garrean S, Hering J, Helton WS, Espat NJ. A primer on transarterial, chemical, and thermal ablative therapies for hepatic tumors. American Journal of Surgery 2007;194(1):79‐88. - PubMed
Gluud 2008
    1. Gluud C, Nikolova D, Klingenberg SL, Whitfield K, Alexakis N, Als‐Nielsen B, et al. Cochrane Hepato‐Biliary Group. About The Cochrane Collaboration (Cochrane Review Groups (CRGs)). 2008, Issue 3. Art. No.: LIVER.
Gupta 2005
    1. Gupta S, Johnson MM, Murthy R, Ahrar K, Wallace MJ, Madoff DC, et al. Hepatic arterial embolization and chemoembolization for the treatment of patients with metastatic neuroendocrine tumors: variables affecting response rates and survival. Cancer 2005;104(8):1590‐602. - PubMed
Higgins 2002
    1. Higgins JPT, Thompson SG. Quantifying heterogeneity in a meta‐analysis. Statistics in Medicine 2002;21(11):1539‐58. - PubMed
Higgins 2008
    1. Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Intervention 5.0.0 [updated February 2008]. The Cochrane Colloboration, 2008. Available from www.cochrane‐handbook.org.
Ito 2003
    1. Ito H, Perez A, Brooks DC, Osteen RT, Zinner MJ, Moore FD Jr, et al. Surgical treatment of small bowel cancer: a 20‐year single institution experience. Journal of Gastrointestinal Surgery 2003;7(7):925‐30. - PubMed
Kjaergard 2001
    1. Kjaergard LL, Villumsen J, Gluud C. Reported methodologic quality and discrepancies between large and small randomized trials in meta‐analyses. Annals of Internal Medicine 2001;135(11):982‐9. - PubMed
Kölby 2003
    1. Kölby L, Persson G, Franzén S, Ahrén B. Randomized clinical trial of the effect of interferon alpha on survival in patients with disseminated midgut carcinoid tumours. The British Journal of Surgery 2003;90:687‐93. - PubMed
Landry 2008
    1. Landry CS, Scoggins CR, McMasters KM, Martin RC 2nd. Management of hepatic metastasis of gastrointestinal carcinoid tumors. Journal of Surgical Oncology 2008;97(3):253‐8. [PUBMED: 18264984] - PubMed
Leblanc 2008
    1. Leblanc F, Fonck M, Brunet R, Becouarn Y, Mathoulin‐Pelissier S, Evrard S. Comparison of hepatic recurrences after resection or intraoperative radiofrequency ablation indicated by size and topographical characteristics of the metastases. European Journal of Surgical Oncology 2008;34(2):185‐90. Epub 2007 Nov 12. - PubMed
Leotlela 2003
    1. Leotlela PD, Jauch A, Holtgreve‐Grez H, Thakker RV. Genetics of neuroendocrine and carcinoid tumours. Endocrine‐related Cancer 2003;10(4):437‐50. - PubMed
Macaskill 2001
    1. Macaskill P, Walter SD, Irwig L. A comparison of methods to detect publication bias in meta‐analysis. Statistics in Medicine 2001;20(4):641‐54. - PubMed
Mazzaglia 2007
    1. Mazzaglia PJ, Berber E, Milas M, Siperstein AE. Laparoscopic radiofrequency ablation of neuroendocrine liver metastases: a 10‐year experience evaluating predictors of survival. Surgery 2007;142(1):10‐9. - PubMed
Modlin 2003
    1. Modlin IM, Lye KD, Kidd M. A 5‐decade analysis of 13,715 carcinoid tumors. Cancer 2003;97(4):934‐59. [PUBMED: 12569593] - PubMed
Moher 1998
    1. Moher D, Pham B, Jones A, Cook DJ, Jadad AR, Moher M, et al. Does quality of reports of randomised trials affect estimates of intervention efficacy reported in meta‐analyses?. Lancet 1998;352(9128):609‐13. - PubMed
Mukherjee 2001
    1. Mukherjee JJ, Kaltsas GA, Islam N, Plowman PN, Foley R, Hikmat J, et al. Treatment of metastatic carcinoid tumours, phaeochromocytoma, paraganglioma and medullary carcinoma of the thyroid with (131)I‐meta‐iodobenzylguanidine [(131)I‐mIBG]. Clinical Endocrinology 2001;55(1):47‐60. - PubMed
NCBI 2008
    1. NCBI. MeSH database. http://www.ncbi.nlm.nih.gov/sites/entrez?db=mesh (last accessed on 2 September 2008).
Newell 1992
    1. Newell DJ. Intention‐to‐treat analysis: implications for quantitative and qualitative research. International Journal of Epidemiology 1992;21(5):837‐41. - PubMed
Nguyen 2004
    1. Nguyen C, Faraggi M, Giraudet AL, Labriolle‐Vaylet C, Aparicio T, Rouzet F, et al. Long‐term efficacy of radionuclide therapy in patients with disseminated neuroendocrine tumors uncontrolled by conventional therapy. Journal of Nuclear Medicine 2004;45(10):1660‐8. - PubMed
Oberg 1989
    1. Oberg K, Norheim I, Alm G. Treatment of malignant carcinoid tumors: a randomized controlled study of streptozocin plus 5‐FU and human leukocyte interferon. European Journal of Cancer & Clinical Oncology 1989;25(10):1475‐9. - PubMed
Pasieka 2004
    1. Pasieka JL, McEwan AJ, Rorstad O. The palliative role of 131I‐MIBG and 111In‐octreotide therapy in patients with metastatic progressive neuroendocrine neoplasms. Surgery 2004;136(6):1218‐26. - PubMed
RevMan 2008 [Computer program]
    1. Copenhagen: The Nordic Cochrane Centre, The Cochrane Collaboration. Review Manager (RevMan). Copenhagen: The Nordic Cochrane Centre, The Cochrane Collaboration, 2008.
Royle 2003
    1. Royle P, Milne R. Literature searching for randomized controlled trials used in Cochrane reviews: rapid versus exhaustive searches. International Journal of Technology Assessment in Health Care 2003;19(4):591‐603. - PubMed
Rubin 1999
    1. Rubin J, Ajani J, Schirmer W, Venook AP, Bukowski R, Pommier R, et al. Octreotide acetate long‐acting formulation versus open‐label subcutaneous octreotide acetate in malignant carcinoid syndrome. Journal of Clinical Oncology 1999;17(2):600‐6. - PubMed
Sarmiento 2003
    1. Sarmiento JM, Heywood G, Rubin J, Ilstrup DM, Nagorney DM, Que FG. Surgical treatment of neuroendocrine metastases to the liver: a plea for resection to increase survival. Journal of the American College of Surgeons 2003;197(1):29‐37. - PubMed
Schulz 1995
    1. Schulz KF, Chalmers I, Hayes RJ, Altman DG. Empirical evidence of bias. Dimensions of methodological quality associated with estimates of treatment effects in controlled trials. JAMA 1995;273(5):408‐12. - PubMed
Sun 2005
    1. Sun W, Lipsitz S, Catalano P, Mailliard JA, Haller DG. Phase II/III study of doxorubicin with fluorouracil compared with streptozocin with fluorouracil or dacarbazine in the treatment of advanced carcinoid tumors: Eastern Cooperative Oncology Group Study E1281. Journal of Clinical Oncology 2005;23(22):4897‐904. - PubMed
Sutherland 2006
    1. Sutherland LM, Williams JA, Padbury RT, Gotley DC, Stokes B, Maddern GJ. Radiofrequency ablation of liver tumors: a systematic review. Archives of Surgery 2006;141(2):181‐90. - PubMed
Sweeting 2004
    1. Sweeting MJ, Sutton AJ, Lambert PC. What to add to nothing? Use and avoidance of continuity corrections in meta‐analysis of sparse data. Statistics in Medicine 2004;23(9):1351‐75. - PubMed
Wangberg 1996
    1. Wangberg B, Westberg G, Tylen U, Tisell L, Jansson S, Nilsson O, et al. Survival of patients with disseminated midgut carcinoid tumors after aggressive tumor reduction. World Journal of Surgery 1996;20(7):892‐9. - PubMed
Wood 2000
    1. Wood TF, Rose DM, Chung M, Allegra DP, Foshag LJ, Bilchik AJ. Radiofrequency ablation of 231 unresectable hepatic tumors: indications, limitations, and complications. Annals of Surgical Oncology 2000;7(8):593‐600. - PubMed
Wood 2008
    1. Wood L, Egger M, Gluud LL, Schulz KF, Jüni P, Altman GD, et al. Empirical evidence of bias in treatment effect estimates in controlled trials with different interventions and outcomes: meta‐epidemiological study. BMJ (Clinical Research Ed.) 2008;336:601‐5. - PMC - PubMed
Yao 2001
    1. Yao KA, Talamonti MS, Nemcek A, Angelos P, Chrisman H, Skarda J, et al. Indications and results of liver resection and hepatic chemoembolization for metastatic gastrointestinal neuroendocrine tumors. Surgery 2001;130(4):677‐85. - PubMed
Zuetenhorst 2005
    1. Zuetenhorst JM, Taal BG. Metastatic carcinoid tumors: a clinical review. The Oncologist 2005;10(2):123‐31. - PubMed

Publication types